troxipide has been researched along with Glioblastoma in 1 studies
troxipide: RN given refers to parent cpd
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooper, E | 1 |
| Choi, PJ | 1 |
| Schweder, P | 1 |
| Mee, E | 1 |
| Turner, C | 1 |
| Faull, R | 1 |
| Denny, WA | 1 |
| Dragunow, M | 1 |
| I-H Park, T | 1 |
| Jose, J | 1 |
1 other study available for troxipide and Glioblastoma
| Article | Year |
|---|---|
Cytoprotective agent troxipide-cyanine dye conjugate with cytotoxic and antiproliferative activity in patient-derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2021 |